Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Aug. 31, 2017	Sep. 26, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Aug. 31, 2017
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q1
Trading Symbol	ANGO
Entity Registrant Name	ANGIODYNAMICS INC
Entity Central Index Key	0001275187
Current Fiscal Year End Date	--05-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		36,715,736

Consolidated Condensed Statements of Income (Loss) (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Aug. 31, 2017	Aug. 31, 2016
Income Statement [Abstract]
Net sales	$ 85,411	$ 88,098
Cost of sales (exclusive of intangible amortization)	44,182	43,066
Gross profit	41,229	45,032
Operating expenses
Research and development	6,441	6,709
Sales and marketing	19,402	19,455
General and administrative	8,056	8,201
Amortization of intangibles	4,096	4,235
Change in fair value of contingent consideration	105	443
Acquisition, restructuring and other items, net	2,989	2,417
Total operating expenses	41,089	41,460
Operating income	140	3,572
Other (expenses) income
Interest expense	(723)	(719)
Other income (expense)	567	50
Total other expenses, net	(156)	(669)
Income (loss) before income tax expense (benefit)	(16)	2,903
Income tax expense	19	1,603
Net income (loss)	$ (35)	$ 1,300
Income (loss) per share
Basic (in usd per share)	$ 0.00	$ 0.04
Diluted (in usd per share)	$ 0.00	$ 0.04
Basic weighted average shares outstanding (in shares)	36,919	36,319
Diluted weighted average shares outstanding (in shares)	36,919	36,698

Consolidated Condensed Statements of Comprehensive Income (Loss) (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Aug. 31, 2017	Aug. 31, 2016
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ (35)	$ 1,300
Other comprehensive income (loss), before tax:
Unrealized gain (loss) on marketable securities	0	(6)
Foreign currency translation (loss)	283	(294)
Other comprehensive income (loss), before tax	283	(300)
Income tax expense related to items of other comprehensive income	0	2
Other comprehensive income (loss), net of tax	283	(298)
Total comprehensive income (loss), net of tax	$ 248	$ 1,002

Consolidated Condensed Balance Sheets (unaudited) - USD ($) $ in Thousands	Aug. 31, 2017	May 31, 2017
CURRENT ASSETS
Cash and cash equivalents	$ 48,200	$ 47,544
Marketable securities	1,215	1,215
Accounts receivable, net of allowances of $3,152 and $2,945, respectively	41,283	44,523
Inventories	55,425	54,506
Prepaid income taxes	312	336
Prepaid expenses and other	4,287	5,790
Total current assets	150,722	153,914
Property, plant and equipment, net	44,353	45,234
Other assets	2,431	1,886
Intangible assets, net	141,583	145,675
Goodwill	361,252	361,252
Total assets	700,341	707,961
CURRENT LIABILITIES
Accounts payable	17,421	18,087
Accrued liabilities	32,264	38,804
Current portion of long-term debt	5,000	5,000
Current portion of contingent consideration	9,638	9,625
Total current liabilities	64,323	71,516
Long-term debt, net of current portion	90,147	91,320
Deferred income taxes	26,030	26,112
Contingent consideration, net of current portion	1,128	3,136
Other long-term liabilities	829	850
Total liabilities	182,457	192,934
Commitments and contingencies (Note 12)
STOCKHOLDERS' EQUITY
Preferred stock, par value $.01 per share, 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, par value $.01 per share, 75,000,000 shares authorized; 37,397,986 and 37,210,091 shares issued and 37,027,986 and 36,840,091 shares outstanding at August 31, 2017 and May 31, 2017, respectively	368	367
Additional paid-in capital	535,511	532,705
Accumulated deficit	(11,240)	(11,007)
Treasury stock, 370,000 shares at August 31, 2017 and May 31, 2017, respectively	(5,714)	(5,714)
Accumulated other comprehensive loss	(1,041)	(1,324)
Total Stockholders’ Equity	517,884	515,027
Total Liabilities and Stockholders' Equity	$ 700,341	$ 707,961

Consolidated Condensed Balance Sheets (unaudited) (Parenthetical) - USD ($) $ in Thousands	Aug. 31, 2017	May 31, 2017
Statement of Financial Position [Abstract]
Accounts receivable, allowances	$ 3,152	$ 2,945
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	37,397,986	37,210,091
Common stock, shares outstanding	37,027,986	36,840,091
Treasury stock, shares	370,000	370,000

Consolidated Condensed Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Aug. 31, 2017	Aug. 31, 2016
Cash flows from operating activities:
Net income (loss)	$ (35)	$ 1,300
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	5,793	6,153
Stock based compensation	1,797	1,684
Change in fair value of contingent consideration	105	443
Gain on contingent consideration for IPR&D Write-off	(82)	1,565
Bad debt expense	278	(197)
Impairment loss on indefinite-lived intangible assets	0	45
Write-off of other assets	(567)	18
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	3,103	2,822
Intercompany	(781)	(3,049)
Prepaid expenses and other	620	(869)
Accounts payable, accrued and other liabilities	(7,195)	(2,475)
Net cash provided by operating activities	3,036	7,440
Cash flows from investing activities:
Additions to property, plant and equipment	(501)	(481)
Net cash used in investing activities	(501)	(481)
Cash flows from financing activities:
Repayment of long-term debt	(1,250)	(2,500)
Payment of acquisition related contingent consideration	(2,100)	(2,100)
Proceeds from exercise of stock options and employee stock purchase plan	812	2,803
Net cash used in financing activities	(2,538)	(1,797)
Effect of exchange rate changes on cash and cash equivalents	659	(84)
Increase in cash and cash equivalents	656	5,078
Cash and cash equivalents at beginning of period	47,544	32,333
Cash and cash equivalents at end of period	48,200	37,411
Supplemental disclosure of non-cash investing and financing activities:
Contractual obligations for acquisition of fixed assets	$ 38	$ 52

Consolidated Condensed Statement of Stockholders' Equity (unaudited) - 3 months ended Aug. 31, 2017 - USD ($) $ in Thousands	Total	Common Stock [Member]	Common Stock [Member] Restricted Stock Units (RSUs) [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Loss [Member]	Treasury Stock [Member]
Beginning Balance at May. 31, 2017	$ 515,027	$ 367		$ 532,705	$ (11,007)	$ (1,324)	$ (5,714)
Beginning Balance, Shares at May. 31, 2017		37,210,091
Beginning Balance,Treasury Shares at May. 31, 2017	(370,000)						(370,000)
Net income (loss)	$ (35)				(35)
Exercise of stock options	89			89
Exercise of stock options, Shares		17,897
Issuance/Cancellation of performance share units and restricted stock units, net	1	$ 1
Issuance/Cancellation of performance share units and restricted stock units, net, Shares			119,098
Purchase of common stock under ESPP	722			722
Purchase of common stock under ESPP, Shares		50,900
Stock based compensation	1,797			1,797
Other comprehensive income, net of tax	283					283
Ending Balance at Aug. 31, 2017	$ 517,884	$ 368		$ 535,511	$ (11,240)	$ (1,041)	$ (5,714)
Ending Balance, Shares at Aug. 31, 2017		37,397,986
Ending Balance,Treasury Shares at Aug. 31, 2017	(370,000)						(370,000)

Consolidated Condensed Financial Statements	3 Months Ended
Consolidated Condensed Financial Statements	Aug. 31, 2017
Accounting Policies [Abstract]
Consolidated Condensed Financial Statements	CONSOLIDATED FINANCIAL STATEMENTS The consolidated balance sheet as of August 31, 2017, the consolidated statement of stockholders’ equity for the three months ended August 31, 2017 and the consolidated statements of income (loss), consolidated statements of comprehensive income (loss), and consolidated statements of cash flows for the three months ended August 31, 2017 and 2016 have been prepared by us and are unaudited. The consolidated balance sheet as of May 31, 2017 was derived from audited consolidated financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary to state fairly the financial position, changes in stockholders’ equity and comprehensive income, results of operations and cash flows as of and for the period ended August 31, 2017 (and for all periods presented) have been made. The unaudited interim consolidated financial statements for the three months ended August 31, 2017 and 2016 include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries, collectively, the “Company”. All intercompany balances and transactions have been eliminated. Reclassifications A reclassification was made to conform the prior year consolidated financial statements to reclassify bad debt expense from Sales and Marketing to General and Administrative. The amount of the reclassification related to fiscal year 2017 is $0.03 million.

Inventories

3 Months Ended

Aug. 31, 2017

Inventory Disclosure [Abstract]

Inventories

INVENTORIES

Inventories are stated at lower of cost (using the first-in, first-out method) or market. As of August 31, 2017 and May 31, 2017, inventories consisted of the following:



	Aug 31, 2017		May 31, 2017
(in thousands)
Raw materials	$	18,389	$	17,563
Work in process	11,313		12,602
Finished goods	25,723		24,341
Inventories	$	55,425	$	54,506

The Company periodically reviews for both obsolescence and loss of value. The Company makes assumptions about the future demand for and market value of the inventory. Based on these assumptions, the Company estimates the amount of obsolete, expiring and slow moving inventory. The total inventory reserve at August 31, 2017 and May 31, 2017 was $5.5 million and $7.3 million, respectively. Of the $5.5 million in the first quarter of fiscal year 2018, $1.2 million relates to the inventory reserve for Acculis inventory as a result of the recall announced in the fourth quarter of fiscal year 2017. Of the $7.3 million in the prior year, $2.4 million relates to the inventory reserve for Acculis inventory as a result of the recall.

Goodwill and Intangible Assets

3 Months Ended

Aug. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

GOODWILL AND INTANGIBLE ASSETS

Intangible assets other than goodwill are amortized over their estimated useful lives on either a straight-line basis or proportionately to the benefit being realized. Useful lives range from two to eighteen years. The Company periodically reviews the estimated useful lives of our intangible assets and review such assets or asset groups for impairment whenever events or changes in circumstances indicate that the carrying value of the assets or asset groups may not be recoverable. If an intangible asset or asset group is considered to be impaired, the amount of the impairment will equal the excess of the carrying value over the fair value of the asset.

Goodwill is not amortized, but rather, is tested for impairment annually or more frequently if impairment indicators arise. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination.

The Company's annual testing for impairment of goodwill was completed as of December 31, 2016. The Company operates as a single operating segment with one reporting unit and consequently evaluates goodwill for impairment based on an evaluation of the fair value of the Company as a whole. The Company determines the fair value of the reporting unit based on the market valuation approach and concluded that it was not more-likely-than-not that the fair value of the Company's reporting unit was less than its carrying value.

Even though the Company determined that there was no goodwill impairment as of December 31, 2016, the future occurrence of a potential indicator of impairment, such as a significant adverse change in legal, regulatory, business or economic conditions or a more-likely-than-not expectation that the reporting unit or a significant portion of the reporting unit will be sold or disposed of, would require an interim assessment for the reporting unit prior to the next required annual assessment as of December 31, 2017. The Company continued to assess for potential impairment through August 31, 2017 and noted no events that would be considered a triggering event. There were no adjustments to goodwill for the three months ended August 31, 2017.

As of August 31, 2017 and May 31, 2017, intangible assets consisted of the following:



	August 31, 2017
	Gross carrying value		Accumulated amortization			Net carrying value
(in thousands)
Product technologies	$	147,172	$	(61,916	)	$	85,256
Customer relationships	56,455		(20,290		)	36,165
Trademarks	28,400		(9,782		)	18,618
Licenses	4,487		(3,919		)	568
Distributor relationships	1,250		(274		)	976
	$	237,764	$	(96,181	)	$	141,583



	May 31, 2017
	Gross carrying value		Accumulated amortization			Net carrying value
(in thousands)
Product technologies	$	147,172	$	(59,696	)	$	87,476
Customer relationships	56,375		(19,194		)	37,181
Trademarks	28,400		(9,069		)	19,331
Licenses	4,487		(3,821		)	666
Distributor relationships	1,250		(229		)	1,021
	$	237,684	$	(92,009	)	$	145,675

Amortization expense for the three months ended August 31, 2017 and 2016 was $4.1 million and $4.2 million, respectively.

Expected future amortization expense related to the intangible assets is as follows:



(in thousands)
Remainder of 2018	$	12,362
2019	16,081
2020	14,525
2021	13,571
2022	12,893
2023 and thereafter	72,151
	$	141,583

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Accrued Liabilities

3 Months Ended

Aug. 31, 2017

Payables and Accruals [Abstract]

Accrued Liabilities

ACCRUED LIABILITIES

As of August 31, 2017 and May 31, 2017, accrued liabilities consisted of the following:



	Aug 31, 2017		May 31, 2017
(in thousands)
Payroll and related expenses	$	6,139	$	11,383
Royalties	2,293		2,885
Accrued severance	1,931		2,075
Sales and franchise taxes	829		856
Outside services	1,899		1,622
Litigation matters	12,500		12,500
Acculis recall liability	1,001		2,563
Other	5,672		4,920
	$	32,264	$	38,804

In the fourth quarter of fiscal year 2017, the Company issued a voluntary recall of its Acculis probes that were sold over the past two years. As of the first quarter of fiscal year 2018, the deferral of revenue related to the Acculis recall was $1.0 million compared to $2.6 million at May 31, 2017.

Long Term Debt

3 Months Ended

Aug. 31, 2017

Debt Disclosure [Abstract]

Long Term Debt

LONG TERM DEBT

On November 7, 2016, the Company entered into a Credit Agreement (the “Credit Agreement”) with the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A. and Keybank National Association as co-syndication agents, and JPMorgan Chase Bank, N.A., Merrill Lynch, Pierce, Fenner & Smith Incorporated and Keybank National Association as joint bookrunners and joint lead arrangers.

The Credit Agreement provides for a $100.0 million senior secured term loan facility (“Term Loan”) and a $150.0 million senior secured revolving credit facility, which includes up to a $20.0 million sublimit for letters of credit and a $5.0 million sublimit for swingline loans (the “Revolving Facility”, and together with the Term Loan, the “Facilities”).

On November 7, 2016, the Company borrowed $100.0 million under the Term Loan and approximately $16.5 million under the Revolving Facility to repay the balance of $116.5 million under the former credit agreement. As of February 28, 2017 the revolver was paid off in full. As of August 31, 2017 and May 31, 2017 the carrying value of long-term debt approximates its fair market value.

The interest rate on the Term Loan at August 31, 2017 was 2.74%.

The Company was in compliance with the Credit Agreement covenants as of August 31, 2017.

The Company's maturities of principal obligations under the Credit Agreement are as follows, as of August 31, 2017:



(in thousands)
Remainder of 2018	$	3,750
2019	5,000
2020	7,500
2021	11,250
2022	68,750
Total term loan	96,250
Revolving facility	—
Total debt	96,250
Less: Unamortized debt issuance costs	(1,103		)
Total	95,147
Less: Current portion of long-term debt	(5,000		)
Total long-term debt, net	$	90,147

Income Taxes	3 Months Ended
Income Taxes	Aug. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES The Company provides for income taxes at the end of each interim period based on the estimated effective tax rate for the full fiscal year adjusted for any discrete events, which are recorded in the period that they occur. The estimated annual effective tax rate prior to discrete items was 52.9% in the first quarter of fiscal 2018, as compared to 55.2% for the same period in fiscal 2017. The Company’s effective tax rate differs from the U.S. statutory rate primarily due to the valuation allowance, the impact of the deferred tax liability related to indefinite lived intangibles, foreign taxes and state taxes. A valuation allowance is established if it is more likely than not that all, or a portion of the deferred tax asset will not be realized. The Company has established that it is more likely than not that some, or all of their deferred tax assets will not be recognized in future years. Consequently, the Company continues to maintain a full U.S. valuation allowance on its net deferred tax assets. Management will continue to reevaluate the positive and negative evidence at each reporting period and if future results as projected in the U.S. and our tax planning strategies are favorable, the valuation allowance may be removed, which could have a favorable material impact on our results of operations in the period in which it is recorded.

Share-Based Compensation	3 Months Ended
Share-Based Compensation	Aug. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation	SHARE-BASED COMPENSATION The Company has two stock-based compensation plans that provide for the issuance of up to approximately 9.5 million shares of common stock. The 2004 Stock and Incentive Award Plan (the "2004 Plan") provides for the grant of incentive options to our employees and for the grant of non-statutory stock options, restricted stock, stock appreciation rights, performance units, performance shares and other incentive awards to our employees, directors and other service providers. The Company also has an employee stock purchase plan. For the three months ended August 31, 2017 and 2016, share-based payment expense was $1.8 million and $1.7 million, respectively. During the three months ended August 31, 2017 and 2016, the Company granted stock options and restricted stock units under the 2004 Plan to certain employees and members of the Board of Directors. Stock option awards are valued using the Black-Scholes option-pricing model and then amortized on a straight-line basis over the requisite service period of the award. Restricted stock unit awards are valued based on the closing trading value of the Company's shares on the date of grant and then amortized on a straight-line basis over the requisite service period of the award. In the first quarter of fiscal year 2018, the Company granted performance share awards under the 2004 Plan to certain employees. The awards may be earned by achieving relative performance levels over the three year requisite service period. The performance criteria are based on the total shareholder return ("TSR") of the Company's common stock relative to the TSR of the common stock of a pre-defined industry peer-group. The fair value of these awards are based on the closing trading value of the Company's shares on the date of grant and use a Monte Carlo simulation model. As of August 31, 2017, there were $18.0 million of unrecognized compensation expenses related to share-based payment arrangements. These costs are expected to be recognized over a weighted-average period of approximately four years. The Company has sufficient shares to satisfy expected share-based payment arrangements.

Earnings Per Share

3 Months Ended

Aug. 31, 2017

Earnings Per Share [Abstract]

Earnings Per Share

EARNINGS PER SHARE

Basic earnings per share is based on the weighted average number of common shares outstanding without consideration of potential common stock. Diluted earnings per share includes the dilutive effect of potential common stock consisting of stock options, restricted stock units and performance stock units, provided that the inclusion of such securities is not anti-dilutive. In periods with a net loss, stock options and restricted stock units are not included in the computation of diluted loss per share as the impact would be anti-dilutive.

The following table reconciles basic to diluted weighted-average shares outstanding for the three months ended August 31, 2017 and 2016 (in thousands):



	Three Months Ended
(in thousands)	Aug 31, 2017	Aug 31, 2016
Basic	36,919	36,319
Effect of dilutive securities	—	379
Diluted	36,919	36,698

Securities excluded as their inclusion would be anti-dilutive	1,085	1,503

Segment and Geographic Information

3 Months Ended

Aug. 31, 2017

Segment Reporting [Abstract]

Segment and Geographic Information

SEGMENT AND GEOGRAPHIC INFORMATION

The Company considers our business to be a single operating segment entity engaged in the development, manufacture and sale of medical devices for vascular access, peripheral vascular disease, oncology and surgery on a global basis. The Company's chief operating decision maker (CEO) evaluates the various global product portfolios on a net sales basis. Executives reporting to the CEO include those responsible for commercial operations, manufacturing operations, regulatory and quality and certain corporate functions. The CEO evaluates profitability, investment and cash flow metrics on a consolidated worldwide basis due to shared infrastructure and resources.

The table below summarizes net sales by product category (in thousands of dollars):



	Three Months Ended
(in thousands)	Aug 31, 2017		Aug 31, 2016
Net sales
Peripheral Vascular	$	49,865	$	52,029
Vascular Access	23,238		25,005
Oncology/Surgery	12,308		11,064
Total	$	85,411	$	88,098

The table below presents net sales by geographic area based on external customer location (in thousands of dollars):



	Three Months Ended
(in thousands)	Aug 31, 2017		Aug 31, 2016
Net sales
United States	$	68,931	$	72,208
International	16,480		15,890
Total	$	85,411	$	88,098

Fair Value

3 Months Ended

Aug. 31, 2017

Fair Value Disclosures [Abstract]

Fair Value

FAIR VALUE

On a recurring basis, the Company measures certain financial assets and financial liabilities at fair value based upon quoted market prices, where available. Where quoted market prices or other observable inputs are not available, the Company applies valuation techniques to estimate fair value. FASB ASC Topic 820, Fair Value Measurements and Disclosures, establishes a three-level valuation hierarchy for disclosure of fair value measurements. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:


•	Level 1 - Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.


•	Level 2 - Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.


•	Level 3 - Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.

The Company's financial instruments include cash and cash equivalents, accounts receivable, marketable securities, accounts payable and contingent consideration. The carrying amount of cash and cash equivalents, accounts receivable, and accounts payable approximates fair value due to the immediate or short-term maturities. The Company's recurring fair value measurements using significant unobservable inputs (Level 3) relate to our marketable securities, which are comprised of auction rate securities, and our contingent consideration liabilities.

The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis as of August 31, 2017 and May 31, 2017 (in thousands of dollars):



	Fair Value Measurements using inputs considered as:						Fair Value at August 31, 2017
(in thousands)	Level 1		Level 2		Level 3
Financial Assets:
Marketable securities
U.S. government agency obligations	$	—	$	—	$	1,215	$	1,215
Total Financial Assets	$	—	$	—	$	1,215	$	1,215
Financial Liabilities:
Contingent consideration for acquisition earn out	$	—	$	—	$	10,766	$	10,766
Total Financial Liabilities	$	—	$	—	$	10,766	$	10,766


	Fair Value Measurements using inputs considered as:						Fair Value at May 31, 2017
(in thousands)	Level 1		Level 2		Level 3
Financial Assets:
Marketable securities
U.S. government agency obligations	$	—	$	—	$	1,215	$	1,215
Total Financial Assets	$	—	$	—	$	1,215	$	1,215
Financial Liabilities:
Contingent consideration for acquisition earn out	$	—	$	—	$	12,761	$	12,761
Total Financial Liabilities	$	—	$	—	$	12,761	$	12,761

There were no transfers between Level 1, 2 and 3 for the three months ended August 31, 2017.

The table below presents the changes in fair value components of Level 3 instruments in the three months ended August 31, 2017 (in thousands of dollars):



	Three Months Ended August 31, 2017
	Financial Assets		Financial Liabilities
(in thousands)	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)		Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Balance, May 31, 2017	$	1,215	$	12,761
Total gains or losses (realized/unrealized):
Change in present value of contingent consideration	—		105
Contingent consideration payments	—		(2,100		)
Balance, August 31, 2017	$	1,215	$	10,766

Contingent Consideration for Acquisition Earn Outs

Some of our business combinations involve the potential for the payment of future contingent consideration upon the achievement of certain product development milestones or various other performance conditions. Payment of the additional consideration is generally contingent on the acquired company reaching certain performance milestones, including attaining specified revenue levels or product development targets. Contingent consideration is recorded at the estimated fair value of the contingent payments on the acquisition date. The fair value of the contingent consideration is remeasured at the estimated fair value at each reporting period with the change in fair value recognized as income or expense within change in fair value of contingent consideration in the consolidated statements of income.

We measure the initial liability and remeasure the liability on a recurring basis using Level 3 inputs as defined under authoritative guidance for fair value measurements and is determined using a discounted cash flow model applied to projected net sales, using probabilities of achieving projected net sales and projected payment dates. Projected net sales are based on our internal projections and extensive analysis of the target market and the sales potential. Increases or decreases in any valuation inputs in isolation may result in a significantly lower or higher fair value measurement in the future.

The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of August 31, 2017 (in thousands of dollars):



	Fair value at		Valuation
(in thousands)	Aug 31, 2017		Technique	Unobservable Input	Range
Revenue based payments	$	10,766	Discounted cash flow	Discount rate	4%
				Probability of payment	100%
				Projected fiscal year of payment	2018-2020

At August 31, 2017, the estimated potential amount of undiscounted future contingent consideration that we expect to pay as a result of all completed acquisitions is approximately $11.0 million, which represents the remaining contractual minimum payments.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Marketable Securities

3 Months Ended

Aug. 31, 2017

Investments, Debt and Equity Securities [Abstract]

Marketable Securities

MARKETABLE SECURITIES

Marketable securities, which can be government agency bonds, auction rate investments or corporate commercial paper, are classified as “available-for-sale securities” and are reported at fair value, with unrealized gains and losses excluded from operations and reported as accumulated other comprehensive income (loss), net of the related tax effects, in stockholders’ equity. Cost is determined using the specific identification method. We hold an investment in an auction rate security that is high credit quality and generally achieved with municipal bond insurance. Sell orders for any security traded through an auction process could exceed bids and, in such cases, the auction fails and we may be unable to liquidate our position in the security in the near term. We have not participated in any recent auctions. As of August 31, 2017 and May 31, 2017, we had $1.2 million and $1.2 million, respectively, in investments in one auction rate security. The authorities are current in their interest payments on the security. The auction rate security will mature in 2029.

As of August 31, 2017 and May 31, 2017, marketable securities consisted of the following (in thousands of dollars):



	August 31, 2017
(in thousands)	Amortized cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Available-for-sale securities:
Government agency obligations	$	1,350	$	—	$	(135	)	$	1,215
	$	1,350	$	—	$	(135	)	$	1,215



	May 31, 2017
(in thousands)	Amortized cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Available-for-sale securities:
Government agency obligations	$	1,350	$	—	$	(135	)	$	1,215
	$	1,350	$	—	$	(135	)	$	1,215

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Aug. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES Legal Proceedings The Company is involved in various legal proceedings, including commercial, intellectual property, product liability, and regulatory matters of a nature considered normal for its business. The Company accrues for amounts related to these matters if it is probable that a liability has been incurred, and an amount can be reasonably estimated. The Company discloses such matters when there is at least a reasonable possibility that a material loss may have been incurred. However, the Company cannot predict the outcome of any litigation or the potential for future litigation. C.R. Bard, Inc. v. AngioDynamics, Inc. On January 11, 2012, C.R. Bard, Inc. (“Bard”) filed a suit in the United States District Court of Utah claiming certain of our implantable port products infringe on three U.S. patents held by Bard (the "Utah Action"). Bard is seeking unspecified damages and other relief. The Court denied Bard’s motion for pre-trial consolidation with separate actions it filed on the same day against Medical Components, Inc. and Smiths Medical ASD, Inc., but had asked for supplemental briefing on the issue of whether to conduct a common Markman hearing. Meanwhile, we filed petitions for reexamination in the US Patent and Trademark Office ("PTO") which seek to invalidate all three patents asserted by Bard in the litigation. Our petitions were granted and 40 of Bard's 41 patent claims were rejected and, following further proceedings, the Patent Office issued a Final Rejection of all 40 claims subject to reexamination. Thereafter, Bard filed appeals to the PTO Board of Appeals and Interferences for all three reexams. The parties completed briefing on the appeals and oral argument was held on June 18, 2015. The Patent Office issued decisions in the three appeals. In one (issued on March 11, 2016 for US Patent No. 7,785,302), the rejections of six of the ten claims under reexamination were affirmed, but were reversed on four of the ten claims. In the second (issued on March 24, 2016 for U.S. Patent No. 7,959,615), the rejections of eight of the ten claims under reexamination were affirmed but the rejections of the other two of the ten claims were reversed. In the third (issued on March 29 for U.S. Patent No. 7,947.022) the rejections of all twenty claims under reexamination were affirmed. Thereafter, Bard filed Requests for Rehearing in all three reexamination appeals and the Company filed Requests for Rehearing in two of the reexamination appeals (the ‘302 and ‘615 patent reexaminations). Each party filed comments in Opposition to the other party’s Rehearing Requests, The PTO has since issued decisions denying all Rehearing Requests on February 1, 2017 for the ‘302; on February 17, 2017 for the ‘022; and on February 21, 2017 for the ‘615. In the ‘302 and ‘022, the PTO modified its characterization of one prior art reference. Bard has since filed a Notice of Appeal to the Federal Circuit Court of Appeals in all three reexams and the Company has filed Cross-Appeals in the ‘302 and the ‘615 reexams. The parties are in the process of preparing and filing the various appellate briefs, starting with Bard’s Opening Brief which was served on August 30, 2017 and ending with our Reply Brief which is currently due on December 6, 2017. The Utah Action has been stayed pending final resolution of the PTO process. However, Bard has moved to substitute Bard Peripheral Vascular, Inc. ("BPV") as plaintiff because Bard assigned the asserted patents to BPV on July 12, 2016, but the Company has opposed. We believe these claims are without merit and intend to defend them vigorously. We have not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable. On March 10, 2015, C.R. Bard, Inc. ("Bard") and Bard Peripheral Vascular, Inc. (“BPV”) filed suit in the United States District Court for the District of Delaware claiming certain of our implantable port products infringe on three U.S. patents held by Bard (the “Delaware Action"). Bard is seeking unspecified damages and other relief. The patents asserted in the Delaware Action are different than those asserted in the Utah Action. On June 1, 2015, the Company filed two motions in response to Bard’s Complaint - one sought transfer to the District of Utah where the Utah Action is currently pending, and the other sought dismissal of the entire complaint on grounds that none of the claims in the asserted patents is directed to patent eligible subject matter under Section 101 of the Patent Statute and in light of recent authority from the U. S. Supreme Court. On January 12, 2016, the court issued a decision denying both motions. We have since served an Answer and Counterclaim to which Bard has served a Reply. On March 10, 2016, the Court held a case management conference, and, on March 14, 2016, the court entered a Scheduling Order which set, inter alia, a Markman hearing for March 10, 2017, a summary judgment hearing for December 8, 2017 and trial for March 12, 2018. The parties have served various discovery requests on each other, and have been producing documents to each other; on May 27, 2016 Bard served its Infringement Contentions which identified all the port products accused of infringement; and, on June 24, 2016, we served Invalidity Contentions which detail various grounds for invalidating the three asserted patents. The parties completed briefing on the claim construction issues and the Markman hearing was held on March 10, 2017 and the Court issued its Claim Construction Order on May 19, 2017. The Court has since amended the Scheduling Order to provide for the completion of Expert Discovery on October 30, 2017; briefing on Case-Dispositive Motions between November 17, 2017 and January 24, 2018 with oral argument set for February 22, 2018 and trial to commence May 29, 2018. Meanwhile, Bard also sought to substitute BPV as plaintiff in this case via a Supplemental Complaint, but stipulated that the Company could assert in Cross-Claims and/or Third-Party complaint against Bard for our claims of inequitable conduct and unclean hands, which the Company has since done. BPV responded with a partial Motion to Dismiss and the Company has served an amended Answer, Counterclaims and Cross-Claims/Third-Party Complaint. BPV/Bard responses are due September 29, 2017. We believe these claims are without merit and intend to defend them vigorously. We have not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable. AngioDynamics, Inc. v. C.R. Bard, Inc. On May 30, 2017, we commenced an action in the United States District Court for the Northern District of New York entitled AngioDynamics, Inc. v. C.R. Bard, Inc. and Bard Access Systems, Inc. (“Bard”). In this action, we allege that Bard has illegally tied the sales of its tip location systems to the sales of its PICCs. We allege that this practice violates the federal antitrust laws and has had, and continues to have, an anti-competitive effect in the market for PICCs. We seek both monetary damages and injunctive relief. Bard moved to dismiss on September 8, 2017 and set a return date of November 16, 2017. The court has adjourned the initial conference in the case pending its resolution of the motion to dismiss. Governmental Investigations In June 2014 we received a subpoena from the U.S. Department of Justice (the “DOJ”) requesting documents in relation to a criminal and civil investigation the DOJ is conducting regarding BTG International, Inc.’s LC Bead® product beginning in 2003. RITA Medical Systems and AngioDynamics, Inc., after its acquisition of RITA, was the exclusive distributor of LC Beads in the United States from 2006 through December 31, 2011. We are cooperating fully with this investigation. In April 2015 we received a subpoena from the DOJ requesting documents in relation to a criminal and civil investigation the DOJ is conducting regarding purported promotion of certain of AngioDynamics’ VenaCure EVLT products for un-cleared indications. We are cooperating fully with this investigation. As of May 31, 2017, the Company accrued $12.5 million for these matters and in August 2017 the Company agreed in principle with the government to resolve these matters for approximately $12.5 million.

Acquisition, Restructuring and Other Items, Net

3 Months Ended

Aug. 31, 2017

Restructuring and Related Activities [Abstract]

Acquisition, Restructuring and Other Items, Net

ACQUISITION, RESTRUCTURING, AND OTHER ITEMS, NET

Acquisition, Restructuring and Other Items

For the three months ended August 31, 2017 and 2016 acquisition, restructuring and other items, net consisted of:



	Three Months Ended
(in thousands)	Aug 31, 2017		Aug 31, 2016
Legal	$	1,764	$	1,790
Restructuring	1,216		—
Other	9		627
Total	$	2,989	$	2,417

Restructuring

The Company evaluates its performance and looks for opportunities to improve the overall operations of the Company on an ongoing basis. As a result of this evaluation, certain restructuring initiatives are taken to enhance the Company’s overall operations.

Operational Consolidation

On February 1, 2017, the Company announced to employees an operational consolidation plan (the “plan”) to consolidate our manufacturing facilities in Manchester, GA and Denmead, UK into the Glens Falls and Queensbury, NY facilities. This plan will streamline and optimize the manufacturing functions into one centralized location increasing the utilization of the Glens Falls and Queensbury facilities, optimizing inventory and reducing cost of goods sold through savings in overhead expenses and direct labor. The restructuring activities associated with the plan are expected to be completed in the third quarter of fiscal year 2018.

The following table provides a summary of our estimated costs associated with the plan:



Type of cost		Total estimated amount expected to be incurred (in millions)
Termination benefits		$1.75 to $2.25
Plant Consolidation (1)		$2.25 to $2.50
Regulatory filings		$0.75 to $1.00
Contract cancellations		$0.75 to $1.00
Other		$0.75 to $1.00
		$6.25 to $7.75

(1) Equipment transfer, validation and other start-up costs to prepare the facilities for the new product lines.

The Company recorded restructuring charges related to the plan during the three months ended August 31, 2017 of $1.2 million. There were no costs associated with this plan during the three months ended August 31, 2016. Termination benefits are only earned if an employee stays until their termination date; therefore, the expenses related to termination benefits are being recorded ratably over the service period.

The following table presents a rollforward of the restructuring reserve for the first quarter of fiscal year 2018:



									Contract
	Termination			Plant			Regulatory		Cancellation		Other
	Benefits			Consolidation			Filings		Costs		Costs			Total
(in thousands)
Balance at May 31, 2017	$	851		$	111		$	—	$	—	$	—		$	962
Charges	594			600			—		—		22			1,216
Non-cash adjustments	—			(108		)	—		—		—			(108		)
Cash payments	(71		)	(555		)	—		—		(21		)	(647		)
Balance at August 31, 2017	$	1,374		$	48		$	—	$	—	$	1		$	1,423

The Company’s restructuring liability of $1.4 million mainly comprises accruals for termination benefits which are included in accrued expenses on the consolidated balance sheet.

Accumulated Other Comprehensive Income

3 Months Ended

Aug. 31, 2017

Equity [Abstract]

Accumulated Other Comprehensive Income

ACCUMULATED OTHER COMPREHESIVE INCOME (LOSS)

Changes in each component of accumulated other comprehensive income (loss), net of tax, are as follows as of August 31, 2017 and 2016:



(in thousands)	Foreign currency translation gain (loss)			Unrealized gain (loss) on marketable securities			Total
Balance at May 31, 2017	$	(1,305	)	$	(19	)	$	(1,324	)
Other comprehensive income (loss) before reclassifications, net of tax	283			—			283
Amounts reclassified from accumulated other comprehensive income	—			—			—
Net other comprehensive income (loss)	$	283		$	—		$	283
Balance at August 31, 2017	$	(1,022	)	$	(19	)	$	(1,041	)

Recently Issued Accounting Pronouncements	3 Months Ended
Recently Issued Accounting Pronouncements	Aug. 31, 2017
Accounting Changes and Error Corrections [Abstract]
Recently Issued Accounting Pronouncements	RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Recently Issued Accounting Pronouncements - Adopted In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Based Compensation (Topic 718: Improvements to Employee Share-Based Payment Accounting). ASU 2016-09 simplifies and improves various aspects of ASC 718 for share-based payments, including income tax items and the classification of these items on the statement of cash flows. ASU 2016-09 is effective for annual periods beginning after December 31, 2016 and early application is permitted. The Company adopted ASU 2016-09 as of June 1, 2017. Under ASU 2016-09, the Company now recognizes unrealized excess tax benefits and will classify such benefits as an operating activity in the statement of cash flows on a prospective basis. Due to the full valuation allowance on our federal and state income taxes, the adoption of ASU 2016-09 did not impact our accounting for income taxes. Without the valuation allowance, we estimate that we would have recognized a deferred tax asset of approximately $0.6 million upon adoption of ASU 2016-09. The Company elected the accounting policy change to account for forfeitures as they occur. This was adopted using the modified retrospective transition method by means of a cumulative-effect adjustment to equity as of June 1, 2017. The adoption of ASU 2016-09 did not materially impact the Company’s consolidated statements of income, consolidated balance sheet, equity or cash flows. In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350), which simplifies the subsequent measurement of goodwill by eliminating steps from the goodwill impairment test. ASU 2017-04 should be adopted for annual or interim goodwill impairment tests in fiscal years beginning after December 15, 2019. ASU 2017-04 should be applied prospectively and early adoption is permitted, including adoption in an interim period. The Company adopted ASU 2017-04 in the first quarter of fiscal year 2018. This adoption did not have an impact on the Company's financial statements. In July 2015, the FASB issued ASC Update No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. Update No. 2015-11 more closely aligns the measurement of inventory in U.S. GAAP with the measurement of inventory in International Financial Reporting Standards by requiring companies using the first-in, first-out and average costs methods to measure inventory using the lower of cost and net realizable value, where net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Update No. 2015-11 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those fiscal years. Update No. 2015-11 should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. This adoption did not have an impact on the Company's financial statements. Recently Issued Accounting Pronouncements - Not Yet Applicable or Adopted In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (ASU 2014-09). ASU 2014-09 provides a single, comprehensive accounting model for revenues arising from contracts with customers that supersedes most of the existing revenue recognition guidance, including industry-specific guidance. Under this model, revenue is recognized at an amount that an entity expects to be entitled to upon transferring control of goods or services to a customer, as opposed to when risks and rewards transfer to a customer under existing revenue recognition guidance. ASU 2014-09 is effective for the Company beginning in its fiscal year 2019, and may be applied retrospectively to all prior periods presented or through a cumulative adjustment to the opening retained earnings balance in the year of adoption. The Company is currently in the process of evaluating the impact of ASU 2014-09 on its consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 increases transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. For leases with a term of twelve months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and liabilities. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 and early application is permitted. The Company is currently in the process of evaluating the impact of ASU 2016-02 on its consolidated financial statements. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (ASU 2016-15). ASU 2016-15 identifies how certain cash receipts and cash payments are presented and classified in the Statement of Cash Flows under Topic 230. ASU 2016-15 is effective for the Company for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. ASU 2016-15 should be applied retrospectively and early adoption is permitted, including adoption in an interim period. The Company is currently in the process of evaluating the impact of ASU 2016-15 on its consolidated financial statements.

Recently Issued Accounting Pronouncements (Policies)	3 Months Ended
Recently Issued Accounting Pronouncements (Policies)	Aug. 31, 2017
Accounting Changes and Error Corrections [Abstract]
Recently Issued Accounting Pronouncements	RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Recently Issued Accounting Pronouncements - Adopted In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Based Compensation (Topic 718: Improvements to Employee Share-Based Payment Accounting). ASU 2016-09 simplifies and improves various aspects of ASC 718 for share-based payments, including income tax items and the classification of these items on the statement of cash flows. ASU 2016-09 is effective for annual periods beginning after December 31, 2016 and early application is permitted. The Company adopted ASU 2016-09 as of June 1, 2017. Under ASU 2016-09, the Company now recognizes unrealized excess tax benefits and will classify such benefits as an operating activity in the statement of cash flows on a prospective basis. Due to the full valuation allowance on our federal and state income taxes, the adoption of ASU 2016-09 did not impact our accounting for income taxes. Without the valuation allowance, we estimate that we would have recognized a deferred tax asset of approximately $0.6 million upon adoption of ASU 2016-09. The Company elected the accounting policy change to account for forfeitures as they occur. This was adopted using the modified retrospective transition method by means of a cumulative-effect adjustment to equity as of June 1, 2017. The adoption of ASU 2016-09 did not materially impact the Company’s consolidated statements of income, consolidated balance sheet, equity or cash flows. In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350), which simplifies the subsequent measurement of goodwill by eliminating steps from the goodwill impairment test. ASU 2017-04 should be adopted for annual or interim goodwill impairment tests in fiscal years beginning after December 15, 2019. ASU 2017-04 should be applied prospectively and early adoption is permitted, including adoption in an interim period. The Company adopted ASU 2017-04 in the first quarter of fiscal year 2018. This adoption did not have an impact on the Company's financial statements. In July 2015, the FASB issued ASC Update No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. Update No. 2015-11 more closely aligns the measurement of inventory in U.S. GAAP with the measurement of inventory in International Financial Reporting Standards by requiring companies using the first-in, first-out and average costs methods to measure inventory using the lower of cost and net realizable value, where net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Update No. 2015-11 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those fiscal years. Update No. 2015-11 should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. This adoption did not have an impact on the Company's financial statements. Recently Issued Accounting Pronouncements - Not Yet Applicable or Adopted In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (ASU 2014-09). ASU 2014-09 provides a single, comprehensive accounting model for revenues arising from contracts with customers that supersedes most of the existing revenue recognition guidance, including industry-specific guidance. Under this model, revenue is recognized at an amount that an entity expects to be entitled to upon transferring control of goods or services to a customer, as opposed to when risks and rewards transfer to a customer under existing revenue recognition guidance. ASU 2014-09 is effective for the Company beginning in its fiscal year 2019, and may be applied retrospectively to all prior periods presented or through a cumulative adjustment to the opening retained earnings balance in the year of adoption. The Company is currently in the process of evaluating the impact of ASU 2014-09 on its consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 increases transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. For leases with a term of twelve months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and liabilities. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 and early application is permitted. The Company is currently in the process of evaluating the impact of ASU 2016-02 on its consolidated financial statements. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (ASU 2016-15). ASU 2016-15 identifies how certain cash receipts and cash payments are presented and classified in the Statement of Cash Flows under Topic 230. ASU 2016-15 is effective for the Company for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. ASU 2016-15 should be applied retrospectively and early adoption is permitted, including adoption in an interim period. The Company is currently in the process of evaluating the impact of ASU 2016-15 on its consolidated financial statements.

Inventories (Tables)

3 Months Ended

Aug. 31, 2017

Inventory Disclosure [Abstract]

Schedule of Inventories

Inventories are stated at lower of cost (using the first-in, first-out method) or market. As of August 31, 2017 and May 31, 2017, inventories consisted of the following:



	Aug 31, 2017		May 31, 2017
(in thousands)
Raw materials	$	18,389	$	17,563
Work in process	11,313		12,602
Finished goods	25,723		24,341
Inventories	$	55,425	$	54,506

Goodwill and Intangible Assets (Tables)

3 Months Ended

Aug. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

As of August 31, 2017 and May 31, 2017, intangible assets consisted of the following:



	August 31, 2017
	Gross carrying value		Accumulated amortization			Net carrying value
(in thousands)
Product technologies	$	147,172	$	(61,916	)	$	85,256
Customer relationships	56,455		(20,290		)	36,165
Trademarks	28,400		(9,782		)	18,618
Licenses	4,487		(3,919		)	568
Distributor relationships	1,250		(274		)	976
	$	237,764	$	(96,181	)	$	141,583



	May 31, 2017
	Gross carrying value		Accumulated amortization			Net carrying value
(in thousands)
Product technologies	$	147,172	$	(59,696	)	$	87,476
Customer relationships	56,375		(19,194		)	37,181
Trademarks	28,400		(9,069		)	19,331
Licenses	4,487		(3,821		)	666
Distributor relationships	1,250		(229		)	1,021
	$	237,684	$	(92,009	)	$	145,675

Schedule of Future Amortization Expense

Expected future amortization expense related to the intangible assets is as follows:



(in thousands)
Remainder of 2018	$	12,362
2019	16,081
2020	14,525
2021	13,571
2022	12,893
2023 and thereafter	72,151
	$	141,583

Accrued Liabilities (Tables)

3 Months Ended

Aug. 31, 2017

Payables and Accruals [Abstract]

Accrued Liabilities

As of August 31, 2017 and May 31, 2017, accrued liabilities consisted of the following:



	Aug 31, 2017		May 31, 2017
(in thousands)
Payroll and related expenses	$	6,139	$	11,383
Royalties	2,293		2,885
Accrued severance	1,931		2,075
Sales and franchise taxes	829		856
Outside services	1,899		1,622
Litigation matters	12,500		12,500
Acculis recall liability	1,001		2,563
Other	5,672		4,920
	$	32,264	$	38,804

Long Term Debt (Tables)

3 Months Ended

Aug. 31, 2017

Debt Disclosure [Abstract]

Schedule of Debt

The Company's maturities of principal obligations under the Credit Agreement are as follows, as of August 31, 2017:



(in thousands)
Remainder of 2018	$	3,750
2019	5,000
2020	7,500
2021	11,250
2022	68,750
Total term loan	96,250
Revolving facility	—
Total debt	96,250
Less: Unamortized debt issuance costs	(1,103		)
Total	95,147
Less: Current portion of long-term debt	(5,000		)
Total long-term debt, net	$	90,147

Earnings Per Share (Tables)

3 Months Ended

Aug. 31, 2017

Earnings Per Share [Abstract]

Reconciliation of Basic to Diluted Weighted-Average Shares Outstanding

The following table reconciles basic to diluted weighted-average shares outstanding for the three months ended August 31, 2017 and 2016 (in thousands):



	Three Months Ended
(in thousands)	Aug 31, 2017	Aug 31, 2016
Basic	36,919	36,319
Effect of dilutive securities	—	379
Diluted	36,919	36,698

Securities excluded as their inclusion would be anti-dilutive	1,085	1,503

Segment and Geographic Information (Tables)

3 Months Ended

Aug. 31, 2017

Segment Reporting [Abstract]

Summary of Net Sales by Product Category

The table below summarizes net sales by product category (in thousands of dollars):



	Three Months Ended
(in thousands)	Aug 31, 2017		Aug 31, 2016
Net sales
Peripheral Vascular	$	49,865	$	52,029
Vascular Access	23,238		25,005
Oncology/Surgery	12,308		11,064
Total	$	85,411	$	88,098

Summary of Net Sales by Geographic Area

The table below presents net sales by geographic area based on external customer location (in thousands of dollars):



	Three Months Ended
(in thousands)	Aug 31, 2017		Aug 31, 2016
Net sales
United States	$	68,931	$	72,208
International	16,480		15,890
Total	$	85,411	$	88,098

Fair Value (Tables)

3 Months Ended

Aug. 31, 2017

Fair Value Disclosures [Abstract]

Fair Value of Assets and Liabilities Measured on a Recurring Basis

The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis as of August 31, 2017 and May 31, 2017 (in thousands of dollars):



	Fair Value Measurements using inputs considered as:						Fair Value at August 31, 2017
(in thousands)	Level 1		Level 2		Level 3
Financial Assets:
Marketable securities
U.S. government agency obligations	$	—	$	—	$	1,215	$	1,215
Total Financial Assets	$	—	$	—	$	1,215	$	1,215
Financial Liabilities:
Contingent consideration for acquisition earn out	$	—	$	—	$	10,766	$	10,766
Total Financial Liabilities	$	—	$	—	$	10,766	$	10,766


	Fair Value Measurements using inputs considered as:						Fair Value at May 31, 2017
(in thousands)	Level 1		Level 2		Level 3
Financial Assets:
Marketable securities
U.S. government agency obligations	$	—	$	—	$	1,215	$	1,215
Total Financial Assets	$	—	$	—	$	1,215	$	1,215
Financial Liabilities:
Contingent consideration for acquisition earn out	$	—	$	—	$	12,761	$	12,761
Total Financial Liabilities	$	—	$	—	$	12,761	$	12,761

Fair Value Measurements Using Significant Unobservable Inputs

The table below presents the changes in fair value components of Level 3 instruments in the three months ended August 31, 2017 (in thousands of dollars):



	Three Months Ended August 31, 2017
	Financial Assets		Financial Liabilities
(in thousands)	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)		Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Balance, May 31, 2017	$	1,215	$	12,761
Total gains or losses (realized/unrealized):
Change in present value of contingent consideration	—		105
Contingent consideration payments	—		(2,100		)
Balance, August 31, 2017	$	1,215	$	10,766

Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability

The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of August 31, 2017 (in thousands of dollars):



	Fair value at		Valuation
(in thousands)	Aug 31, 2017		Technique	Unobservable Input	Range
Revenue based payments	$	10,766	Discounted cash flow	Discount rate	4%
				Probability of payment	100%
				Projected fiscal year of payment	2018-2020

Marketable Securities (Tables)

3 Months Ended

Aug. 31, 2017

Investments, Debt and Equity Securities [Abstract]

Marketable Securities

As of August 31, 2017 and May 31, 2017, marketable securities consisted of the following (in thousands of dollars):



	August 31, 2017
(in thousands)	Amortized cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Available-for-sale securities:
Government agency obligations	$	1,350	$	—	$	(135	)	$	1,215
	$	1,350	$	—	$	(135	)	$	1,215



	May 31, 2017
(in thousands)	Amortized cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Available-for-sale securities:
Government agency obligations	$	1,350	$	—	$	(135	)	$	1,215
	$	1,350	$	—	$	(135	)	$	1,215

Acquisition, Restructuring and Other Items, Net (Tables)

3 Months Ended

Aug. 31, 2017

Restructuring and Related Activities [Abstract]

Restructuring and Related Costs

the first quarter of fiscal year 2018:



									Contract
	Termination			Plant			Regulatory		Cancellation		Other
	Benefits			Consolidation			Filings		Costs		Costs			Total
(in thousands)
Balance at May 31, 2017	$	851		$	111		$	—	$	—	$	—		$	962
Charges	594			600			—		—		22			1,216
Non-cash adjustments	—			(108		)	—		—		—			(108		)
Cash payments	(71		)	(555		)	—		—		(21		)	(647		)
Balance at August 31, 2017	$	1,374		$	48		$	—	$	—	$	1		$	1,423

The following table provides a summary of our estimated costs associated with the plan:



Type of cost		Total estimated amount expected to be incurred (in millions)
Termination benefits		$1.75 to $2.25
Plant Consolidation (1)		$2.25 to $2.50
Regulatory filings		$0.75 to $1.00
Contract cancellations		$0.75 to $1.00
Other		$0.75 to $1.00
		$6.25 to $7.75

For the three months ended August 31, 2017 and 2016 acquisition, restructuring and other items, net consisted of:



	Three Months Ended
(in thousands)	Aug 31, 2017		Aug 31, 2016
Legal	$	1,764	$	1,790
Restructuring	1,216		—
Other	9		627
Total	$	2,989	$	2,417

Accumulated Other Comprehensive Income (Tables)

3 Months Ended

Aug. 31, 2017

Equity [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

Changes in each component of accumulated other comprehensive income (loss), net of tax, are as follows as of August 31, 2017 and 2016:



(in thousands)	Foreign currency translation gain (loss)			Unrealized gain (loss) on marketable securities			Total
Balance at May 31, 2017	$	(1,305	)	$	(19	)	$	(1,324	)
Other comprehensive income (loss) before reclassifications, net of tax	283			—			283
Amounts reclassified from accumulated other comprehensive income	—			—			—
Net other comprehensive income (loss)	$	283		$	—		$	283
Balance at August 31, 2017	$	(1,022	)	$	(19	)	$	(1,041	)

Inventories - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Aug. 31, 2017	May 31, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 18,389	$ 17,563
Work in process	11,313	12,602
Finished goods	25,723	24,341
Inventories	$ 55,425	$ 54,506

Inventories - Narrative (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
Inventories - Narrative (Details) - USD ($) $ in Millions	Aug. 31, 2017	May 31, 2017
Inventory Disclosure [Abstract]
Inventory valuation reserves	$ 5.5	$ 7.3
Inventory write-down	$ 1.2	$ 2.4

Goodwill and Intangible Assets - Narrative (Detail) - USD ($)		3 Months Ended		12 Months Ended
	Dec. 31, 2016	Aug. 31, 2017	Aug. 31, 2016	May 31, 2017
Finite-Lived Intangible Assets [Line Items]
Goodwill impairment	$ 0
Goodwill adjustments				$ 0
Amortization of intangibles		$ 4,096,000	$ 4,235,000
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets other than goodwill				18 years
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets other than goodwill		2 years

Goodwill and Intangible Assets - Intangible Assets (Detail) - USD ($) $ in Thousands	Aug. 31, 2017	May 31, 2017
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, excluding goodwill	$ 237,764	$ 237,684
Accumulated amortization	(96,181)	(92,009)
Net carrying value, finite intangible items	141,583
Net carrying value, excluding goodwill	141,583	145,675
Product Technologies [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items	147,172	147,172
Accumulated amortization	(61,916)	(59,696)
Net carrying value, finite intangible items	85,256	87,476
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items	56,455	56,375
Accumulated amortization	(20,290)	(19,194)
Net carrying value, finite intangible items	36,165	37,181
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items	28,400	28,400
Accumulated amortization	(9,782)	(9,069)
Net carrying value, finite intangible items	18,618	19,331
Licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items	4,487	4,487
Accumulated amortization	(3,919)	(3,821)
Net carrying value, finite intangible items	568	666
Distributor Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items	1,250	1,250
Accumulated amortization	(274)	(229)
Net carrying value, finite intangible items	$ 976	$ 1,021

Goodwill and Intangible Assets - Expected Future Amortization Expense (Details) $ in Thousands	Aug. 31, 2017 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2017	$ 12,362
2018	16,081
2019	14,525
2020	13,571
2021	12,893
2022 and thereafter	72,151
Net carrying value, finite intangible items	$ 141,583

Accrued Liabilities - Summary of Accrued Liabilities (Detail) - USD ($) $ in Thousands	Aug. 31, 2017	May 31, 2017
Other Liabilities Disclosure [Abstract]
Payroll and related expenses	$ 6,139	$ 11,383
Royalties	2,293	2,885
Accrued severance	1,931	2,075
Sales and franchise taxes	829	856
Outside services	1,899	1,622
Accrued Litigation	12,500	12,500
Accrued Acculis Recall	1,001	2,563
Other	5,672	4,920
Total	$ 32,264	$ 38,804

Long Term Debt - Narrative (Detail) - USD ($)		3 Months Ended
Long Term Debt - Narrative (Detail) - USD ($)	Nov. 07, 2016	Aug. 31, 2017	Aug. 31, 2016
Debt Instrument [Line Items]
Repayments of former credit agreement		$ 1,250,000	$ 2,500,000
Credit Facility \| JPMorgan Chase Bank, N.A., Bank of America, N.A., Keybank National Association [Member]
Debt Instrument [Line Items]
Stated interest rate		2.74%
Term Loan \| Credit Facility \| JPMorgan Chase Bank, N.A., Bank of America, N.A., Keybank National Association [Member]
Debt Instrument [Line Items]
Line of credit	$ 100,000,000
Proceeds from issuance of and borrowings on long-term debt	100,000,000
Revolving Credit Facility \| Credit Facility \| JPMorgan Chase Bank, N.A., Bank of America, N.A., Keybank National Association [Member]
Debt Instrument [Line Items]
Line of credit	150,000,000
Proceeds from issuance of and borrowings on long-term debt	16,500,000
Letter of Credit [Member] \| Credit Facility \| JPMorgan Chase Bank, N.A., Bank of America, N.A., Keybank National Association [Member]
Debt Instrument [Line Items]
Line of credit	20,000,000
Bridge Loan [Member] \| Credit Facility \| JPMorgan Chase Bank, N.A., Bank of America, N.A., Keybank National Association [Member]
Debt Instrument [Line Items]
Line of credit	5,000,000
Former Credit Agreement [Member] \| Credit Facility \| JPMorgan Chase Bank, N.A., Bank of America, N.A., Keybank National Association [Member]
Debt Instrument [Line Items]
Repayments of former credit agreement	$ 116,500,000

Long Term Debt - Debt Outstanding (Details) - USD ($) $ in Thousands	Aug. 31, 2017	May 31, 2017
Debt Instrument [Line Items]
Long term debt, gross	$ 96,250
Unamortized debt issuance costs	(1,103)
Long term debt, net	95,147
Current portion of long term debt	(5,000)	$ (5,000)
Long term debt, net of current maturities	90,147
Term Loan \| Credit Facility
Debt Instrument [Line Items]
Remainder of 2018	3,750
2019	5,000
2020	7,500
2021	11,250
2022	68,750
Long term debt, gross	96,250
Revolving Credit Facility \| Credit Facility
Debt Instrument [Line Items]
Long term debt, gross	$ 0

Share-Based Compensation - Narrative (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Aug. 31, 2017	Aug. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Amount of shares issuable through two stock-based compensation plans	9.5
Charges against income for share-based payment arrangements	$ 1.8	$ 1.7
Unrecognized compensation expenses related to share-based payment arrangements	$ 18.0
Recognition period	4 years

Earnings Per Share - Reconciliation of Basic to Diluted Weighted-Average Shares Outstanding (Detail) - shares shares in Thousands	3 Months Ended
	Aug. 31, 2017	Aug. 31, 2016
Earnings Per Share [Abstract]
Basic (shares)	36,919	36,319
Effect of dilutive securities (shares)	0	379
Diluted (shares)	36,919	36,698
Securities excluded as their inclusion would be anti-dilutive (shares)	1,085	1,503

Segment and Geographic Information - Summary of Net Sales by Product Category (Detail) - USD ($) $ in Thousands	3 Months Ended
	Aug. 31, 2017	Aug. 31, 2016
Segment Reporting Information [Line Items]
Net sales	$ 85,411	$ 88,098
Peripheral Vascular [Member]
Segment Reporting Information [Line Items]
Net sales	49,865	52,029
Vascular Access [Member]
Segment Reporting Information [Line Items]
Net sales	23,238	25,005
Oncology/Surgery [Member]
Segment Reporting Information [Line Items]
Net sales	$ 12,308	$ 11,064

Segment and Geographic Information - Summary of Net Sales by Geographic Area (Detail) - USD ($) $ in Thousands	3 Months Ended
	Aug. 31, 2017	Aug. 31, 2016
Net Sales
Net sales	$ 85,411	$ 88,098
Reportable Geographical Components [Member] \| United States [Member]
Net Sales
Net sales	68,931	72,208
Reportable Geographical Components [Member] \| International [Member]
Net Sales
Net sales	$ 16,480	$ 15,890

Fair Value - Fair Value of Assets and Liabilities Measured on a Recurring Basis (Detail) - USD ($) $ in Thousands	Aug. 31, 2017	May 31, 2017
Recurring [Member]
Financial Assets
Total Financial Assets	$ 1,215	$ 1,215
Financial Liabilities
Total Financial Liabilities	10,766	12,761
Recurring [Member] \| U.S. Government Agency Obligations [Member]
Financial Assets
Marketable securities	1,215	1,215
Contingent Consideration Earn Out Liability [Member]
Financial Liabilities
Total Financial Liabilities	10,766
Contingent Consideration Earn Out Liability [Member] \| Recurring [Member]
Financial Liabilities
Total Financial Liabilities		12,761
Level 1 [Member] \| Recurring [Member]
Financial Assets
Total Financial Assets	0	0
Financial Liabilities
Total Financial Liabilities	0	0
Level 1 [Member] \| Recurring [Member] \| U.S. Government Agency Obligations [Member]
Financial Assets
Marketable securities	0	0
Level 1 [Member] \| Contingent Consideration Earn Out Liability [Member] \| Recurring [Member]
Financial Liabilities
Total Financial Liabilities	0
Level 2 [Member] \| Recurring [Member]
Financial Assets
Total Financial Assets	0	0
Financial Liabilities
Total Financial Liabilities	0	0
Level 2 [Member] \| Recurring [Member] \| U.S. Government Agency Obligations [Member]
Financial Assets
Marketable securities	0	0
Level 2 [Member] \| Contingent Consideration Earn Out Liability [Member] \| Recurring [Member]
Financial Liabilities
Total Financial Liabilities	0
Level 3 [Member] \| Recurring [Member]
Financial Assets
Total Financial Assets	1,215	1,215
Financial Liabilities
Total Financial Liabilities	10,766	12,761
Level 3 [Member] \| Recurring [Member] \| U.S. Government Agency Obligations [Member]
Financial Assets
Marketable securities	1,215	1,215
Level 3 [Member] \| Contingent Consideration Earn Out Liability [Member] \| Recurring [Member]
Financial Liabilities
Total Financial Liabilities	$ 10,766	$ 12,761

Fair Value - Fair Value Measurements Using Significant Unobservable Inputs (Detail) $ in Thousands	3 Months Ended
	Aug. 31, 2017 USD ($)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Financial assets, begining balance	$ 1,215
Contingent consideration - Clinical Devices, assets	0
Financial assets, ending balance	1,215
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Financial liabilities, begining balance	12,761
Change in Fair Value of Contingent Consideration	105
Financial liabilities, ending balance	10,766
Clinical Devices B.V [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Contingent consideration - Clinical Devices, liabilities	$ (2,100)

Fair Value - Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability (Detail) - USD ($) $ in Thousands	3 Months Ended
	Aug. 31, 2017	May 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value	$ 10,766	$ 12,761
Level 3 [Member] \| Revenue Based Payments [Member] \| Recurring [Member] \| Contingent Consideration Earn Out Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value	$ 10,766
Discount rate	4.00%
Probability of payment	100.00%

Marketable Securities - Narrative (Detail) $ in Millions	Aug. 31, 2017 USD ($) Investment	May 31, 2017 USD ($)
Marketable Securities [Abstract]
Investments in auction rate securities that failed auctions \| $	$ 1.2	$ 1.2
Number of investments (investment) \| Investment	1

Marketable Securities - Marketable Securities (Detail) - USD ($) $ in Thousands	Aug. 31, 2017	May 31, 2017
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	$ 1,350	$ 1,350
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(135)	(135)
Fair Value	1,215	1,215
U.S. Government Agency Obligations [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	1,350	1,350
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(135)	(135)
Fair Value	$ 1,215	$ 1,215

Commitments and Coontingencies - Additional Information (Detail) $ in Millions							3 Months Ended	9 Months Ended
	Mar. 29, 2016 claim	Mar. 24, 2016 claim	Mar. 11, 2016 claim	Jun. 01, 2015 motion	Mar. 10, 2015 patent	Jan. 11, 2012 reexamination_appeal claim	Aug. 31, 2017 claim	Feb. 28, 2017 Petition reexamination_appeal	May 31, 2017 USD ($)
Loss Contingencies [Line Items]
Loss Contingency Accrual \| $									$ 12.5
C.R. Bard, Inc. [Member]
Loss Contingencies [Line Items]
Number of petitions filed for reexamination of patents \| Petition								3
Number of claims dismissed							40,000
The Utah Action [Member]
Loss Contingencies [Line Items]
Patent claims						41,000
Number of claims dismissed	20	8	6			40
Number of reexaminations \| reexamination_appeal						3
Number of pending claims		10	10
Number of claims reversed		2	4
The Utah Action [Member] \| Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of reexaminations \| reexamination_appeal								2
The Delaware Action [Member]
Loss Contingencies [Line Items]
Number of patents allegedly infringed upon				2	3
C.R. Bard, Inc. [Member] \| The Utah Action [Member] \| Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of reexaminations \| reexamination_appeal								3

Acquisition, Restructuring and Other Items, Net - Summary (Details) - USD ($) $ in Thousands	3 Months Ended
	Aug. 31, 2017	Aug. 31, 2016
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net	$ 2,989	$ 2,417
Legal Costs [Member]
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net	1,764	1,790
Facility Closing [Member]
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net	1,216	0
Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net	$ 9	$ 627

Acquisition, Restructuring and Other Items, Net - Expected Restructuring Costs (Details) $ in Thousands	Feb. 01, 2017 USD ($)
Minimum [Member]
Restructuring Cost and Reserve [Line Items]
Estimated costs	$ 6,250
Minimum [Member] \| One-time Termination Benefits [Member]
Restructuring Cost and Reserve [Line Items]
Estimated costs	1,750
Minimum [Member] \| Equipment Transfer [Member]
Restructuring Cost and Reserve [Line Items]
Estimated costs	2,000
Minimum [Member] \| Regulatory Filings [Member]
Restructuring Cost and Reserve [Line Items]
Estimated costs	800
Minimum [Member] \| Contract Termination [Member]
Restructuring Cost and Reserve [Line Items]
Estimated costs	800
Minimum [Member] \| Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Estimated costs	800
Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Estimated costs	7,750
Maximum [Member] \| One-time Termination Benefits [Member]
Restructuring Cost and Reserve [Line Items]
Estimated costs	2,250
Maximum [Member] \| Equipment Transfer [Member]
Restructuring Cost and Reserve [Line Items]
Estimated costs	2,500
Maximum [Member] \| Regulatory Filings [Member]
Restructuring Cost and Reserve [Line Items]
Estimated costs	1,000
Maximum [Member] \| Contract Termination [Member]
Restructuring Cost and Reserve [Line Items]
Estimated costs	1,000
Maximum [Member] \| Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Estimated costs	$ 1,000

Acquisition, Restructuring and Other Items, Net - Narrative (Details) - USD ($)	3 Months Ended	12 Months Ended
	Aug. 31, 2017	May 31, 2016	May 31, 2017
Restructuring and Related Activities [Abstract]
Restructuring charges	$ 1,216,000	$ 0
Restructuring liability	$ 1,423,000		$ 962,000

Acquisition, Restructuring and Other Items, Net - Costs Incurred (Details) - USD ($)	3 Months Ended	12 Months Ended
	Aug. 31, 2017	May 31, 2016
Restructuring Cost and Reserve [Line Items]
Restructuring reserve, beginning balance	$ 962,000
Charges	1,216,000	$ 0
Non-cash adjustments	(108,000)
Cash payments	(647,000)
Restructuring reserve, ending balance	1,423,000
One-time Termination Benefits [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserve, beginning balance	851,000
Charges	594,000
Non-cash adjustments	0
Cash payments	(71,000)
Restructuring reserve, ending balance	1,374,000
Plants Consolidation
Restructuring Cost and Reserve [Line Items]
Restructuring reserve, beginning balance	111,000
Charges	600,000
Non-cash adjustments	(108,000)
Cash payments	(555,000)
Restructuring reserve, ending balance	48,000
Regulatory Filings [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserve, beginning balance	0
Charges	0
Non-cash adjustments	0
Cash payments	0
Restructuring reserve, ending balance	0
Contract Termination [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserve, beginning balance	0
Charges	0
Non-cash adjustments	0
Cash payments	0
Restructuring reserve, ending balance	0
Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserve, beginning balance	0
Charges	22,000
Non-cash adjustments	0
Cash payments	(21,000)
Restructuring reserve, ending balance	$ 1,000

Accumulated Other Comprehensive Income - Schedule (Details) - USD ($) $ in Thousands	3 Months Ended
	Aug. 31, 2017	Aug. 31, 2016	May 31, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss	$ (1,041)		$ (1,324)
Other comprehensive income (loss) before reclassifications, net of tax	283
Amounts reclassified from accumulated other comprehensive income	0
Net other comprehensive income (loss)	283	$ (298)
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss	(1,022)		(1,305)
Other comprehensive income (loss) before reclassifications, net of tax	283
Amounts reclassified from accumulated other comprehensive income	0
Net other comprehensive income (loss)	283
Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss	(19)		$ (19)
Other comprehensive income (loss) before reclassifications, net of tax	0
Amounts reclassified from accumulated other comprehensive income	0
Net other comprehensive income (loss)	$ 0

Income Taxes - Additional Information (Detail)	3 Months Ended
Income Taxes - Additional Information (Detail)	Aug. 31, 2017	Aug. 31, 2016
Income Tax Disclosure [Abstract]
Estimated federal statutory income tax rate	52.90%	55.20%

Fair Value - Additional Information (Detail) $ in Millions	Aug. 31, 2017 USD ($)
Fair Value Disclosures [Abstract]
Potential amount of undiscounted future contingent consideration	$ 11.0

Consolidated Condensed Financial Statements Consolidated Condensed Financial Statements - Additional Information (Details) $ in Thousands	3 Months Ended
	Aug. 31, 2017 USD ($)
Accounting Policies [Abstract]
Reclassification, Bad Debt Expense	$ 30